Dey Pharma, LP v. SUNOVION PHARMACEUTICALS INC.
677 F.3d 1158
Fed. Cir.2012Background
- Dey filed a declaratory judgment action in June 2008 seeking invalidity or noninfringement of Sunovion's '289 patent related to Xopenex.
- Sunovion listed three Orange Book patents ('755, '994, and '289') with '289 expiring in 2021.
- Breath (first ANDA filer) had earlier filed for generic Xopenex with paragraph IV, triggering brand-vs-generic litigation dynamics.
- Sunovion sued Breath for the '755' and '994' patents; the Breath case settled, allowing generic entry in 2012 under settlement terms.
- Dey later filed a second ANDA with paragraph IV; Sunovion sued over two patents but not the '289 patent, and the actions were consolidated.
- The district court denied Sunovion's jurisdictional challenge, and Dey obtained a final judgment of noninfringement in 2011; Sunovion appealed on jurisdiction.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether DJ jurisdiction existed in June 2008 | Dey argues jurisdiction existed under Caraco and Janssen because it seeks to remove a gating patent that excludes market entry. | Sunovion contends lack of immediate controversy since first patent dispute remained unresolved and exclusivity timing complicates redressability. | Yes; jurisdiction existed in June 2008. |
| Whether a covenant not to sue moots the case | Dey's injury remains redressable despite covenant because other barriers could still block entry. | Sunovion argues covenant defeats jurisdiction entirely. | Covenant does not moot; jurisdiction remains. |
| Whether the case becomes moot after Breath's entry timing | Even if Breath delays entry, potential mootness requires actual triggering of exclusivity; jurisdiction persists until mootness is shown. | Sunovion contends mootness could arise once Breath markets, eliminating controversy. | Case may proceed until mootness is shown. |
Key Cases Cited
- Caraco Pharm. Labs., Ltd. v. Forest Labs., Inc., 527 F.3d 1278 (Fed.Cir. 2008) (declaratory jurisdiction when first drug is potentially excluded from market)
- Janssen Pharmaceutica, N.V. v. Teva Pharms. USA, Inc., 540 F.3d 1353 (Fed.Cir. 2008) (jurisdiction depends on whether later patents create immediate barriers)
- MedImmune, Inc. v. Genentech, Inc., 549 U.S. 118 (2007) (declaratory judgment jurisdiction requires substantial controversy with immediacy)
- Teva Pharms. USA, Inc. v. Novartis Pharms. Corp., 482 F.3d 1330 (Fed.Cir. 2007) (context of Hatch-Waxman and reasonable anticipation of infringement actions)
- Cardinal Chem. Co. v. Morton Int’l, Inc., 508 U.S. 83 (U.S. 1993) (principle that mootness burdens lie with the party asserting mootness)
- Arizonans for Official English v. Arizona, 520 U.S. 43 (U.S. 1997) (mootness and ongoing jurisdiction considerations in Supreme Court precedent)